| Ms Mary Cathleen Healy, | |
|
Rts 4 & 12, Taftsville, VT 05073 | |
| (802) 457-4487 | |
| Not Available |
| Full Name | Ms Mary Cathleen Healy |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Pediatrics |
| Location | Rts 4 & 12, Taftsville, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053486951 | NPI | - | NPPES |
| 1308739Y0VT01 | Other | NH | ANTHEM |
| 19119 | Other | VT | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | 072-0000071 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Mary Cathleen Healy, Po Box 349, Norwich, VT 05055-0349 Ph: () - | Ms Mary Cathleen Healy, Rts 4 & 12, Taftsville, VT 05073 Ph: (802) 457-4487 |
News Archive
MPMN and PlasticsToday.com, both leading news and information providers for the medical device and plastics industry, today announced the launch of a new conference on Innovations in Medical Polymers, providing insights into the latest technological and regulatory developments in the use of polymers in medical devices.
Researchers at UC San Diego who last year genetically engineered bacteria to keep track of time by turning on and off fluorescent proteins within their cells have taken another step toward the construction of a programmable genetic sensor. The scientists recently synchronized these bacterial "genetic clocks" to blink in unison and engineered the bacterial genes to alter their blinking rates when environmental conditions change.
For their unique Return to Work Lab which focuses on individualized rehabilitation for younger, more active cardiac patients, the Cardiac Rehabilitation program at the Baylor Jack and Jane Hamilton Heart and Vascular Hospital was recently awarded the Innovation Award from the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR).
BioCryst Pharmaceuticals, Inc. presents new results from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in patients with gout who have failed to reach the clinically important serum uric acid (sUA) goal of <6 mg/dL on allopurinol alone.
› Verified 4 days ago
Ms. Heather Marie Rizk, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Intersections Of Rts 4 And 12, Taftsville, VT 05073 Phone: 802-457-4487 Fax: 802-457-9428 |